A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. - Wikidata - awgldk - TriplyDB

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.

http://www.wikidata.org/entity/Q41102009

about

Weight-based dosing in medication use: what should we know?Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors.Role of the N-acetylation polymorphism in solithromycin metabolism.

P2860

Q26750730-6EECB6C2-3952-4492-994B-EE5E0F0C1C60 Q28079207-3019965E-5F1B-4C87-8E98-08995823D430 Q36247566-CE446128-D2A8-4ED5-B765-50203FCA0F36 Q37287653-93BD0203-81ED-4842-AD66-52398D4686E3 Q40096207-56770A0A-039D-4506-B104-667F68A31FC3 Q40592548-646F39D7-FF18-4DEF-9776-BD2CD348DA11 Q41068782-D46E517C-49C3-4D26-B78D-9A9C2A25F103 Q42335970-66D3D4EC-7DE4-4AD6-9915-234272A1E8DF Q42696912-CDA4D4A1-D23E-42BD-A05B-FE2B72197CC0 Q47715776-94CB83C6-39A9-47DF-AB0E-90F5A7009652 Q55154837-6B331867-25C8-4262-9CA4-198DCE2F6E69

P2860

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.

http://www.wikidata.org/entity/Q41102009

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A proposal for an individualiz ...... or patients with tuberculosis.

@en

type

label

A proposal for an individualiz ...... or patients with tuberculosis.

@en

prefLabel

A proposal for an individualiz ...... or patients with tuberculosis.

@en

P1433

Q41102009-6429043E-5A7E-4997-9E16-8AF153EF7583

P1476

Q41102009-1B077AEF-4985-41B4-BBD7-BA5489A26418

P2093

Q41102009-1136759D-0606-4768-9426-AE2653AFE7CB

Q41102009-16DD3707-13C7-40D4-BEF9-C5B632137667

Q41102009-3AC02AE2-EE5E-47BC-9E5E-71D51EB719ED

Q41102009-3B3B5A8D-01B2-4E83-AF82-241A952AB9DD

Q41102009-601AA955-71C3-4706-BC82-DA6E384C2060

Q41102009-76B1454F-DFB8-40AE-8321-D1C2C0D1D533

Q41102009-A8A9609D-B507-4468-9A6C-366789DDA3BC

Q41102009-A9E77504-CA9E-436B-A937-13CC5E0996EA

Q41102009-C2951500-16A1-4B1B-8173-9D38DFECE885

Q41102009-DA2FA30B-183F-4165-9B07-3076BADE5C94

P2860

Q41102009-005A8D1F-8A62-435B-BA55-D28685FD2D6F

Q41102009-269FEA85-4C09-4F82-A53A-C29D7545B180

Q41102009-2A20BF55-B19F-4314-A25D-A7D442E3CAF2

Q41102009-36FA968A-E462-4DCA-B7AE-0349F0454C46

Q41102009-43A094D9-D15B-4B25-8625-EBC27CAF7362

Q41102009-43BC20D0-C0AD-4268-BD9E-4DFFB825B010

Q41102009-5915E478-93A1-4F17-AD7F-CA46D405DBE5

Q41102009-69EC53BE-168C-4978-867E-4D283655BCD6

Q41102009-9DD114EF-1AD6-4D9C-BD57-58EEC0DF73EF

Q41102009-A17ABDD4-5CC0-43CB-A78F-D18C6804AA08

P304

Q41102009-96970F09-7160-4856-A03D-8CD5D1784F9E

P31

Q41102009-51C7F713-A57E-45DB-9489-A234F9B6B3C4

P356

Q41102009-2EB0449A-D10B-41CC-88E6-EF361F2CDBBC

P407

Q41102009-2B75EE91-FA22-4325-A44C-505A642EC098

P478

Q41102009-83A45107-9C06-4258-94DC-4C76791BC5EC

P50

Q41102009-2D1A4D0C-618F-4A1B-8F71-23E7EB9AD84D

P577

Q41102009-BFCDA1B5-5942-4C5B-96A4-F753BB35395B

P698

Q41102009-181FDF93-1698-4761-8669-FBA843A33A3E

P932

Q41102009-7F8283F7-C9C8-44AF-8B50-982415A2BA07

P356

P1433

Drug Design, Development and Therapy

P1476

A proposal for an individualiz ...... for patients with tuberculosis

@en

P2093

Hye Yun Park

http://www.w3.org/2001/XMLSchema#string

Hye-In Woo

http://www.w3.org/2001/XMLSchema#string

Hyun Lee

http://www.w3.org/2001/XMLSchema#string

Jae-Wook Ko

http://www.w3.org/2001/XMLSchema#string

Jin Ah Jung

http://www.w3.org/2001/XMLSchema#string

Kyeongman Jeon

http://www.w3.org/2001/XMLSchema#string

O Jung Kwon

http://www.w3.org/2001/XMLSchema#string

Rihwa Choi

http://www.w3.org/2001/XMLSchema#string

Soo-Youn Lee

http://www.w3.org/2001/XMLSchema#string

Tae-Eun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Criteria of drug-induced liver disorders. Report of an international consensus meeting.

Therapeutic drug monitoring in the treatment of tuberculosis.

Therapeutic drug monitoring in the treatment of active tuberculosis

Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.

Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.

P304

5433-5438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S87131

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Byeong-Ho Jeong

P577

2015-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26491254

http://www.w3.org/2001/XMLSchema#string

P932

4598210

http://www.w3.org/2001/XMLSchema#string